WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association
WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association for Cancer Research Dr Lana Kandalaft from the University of Pennsylvania in Philadelphia explained this was the first time a combination of dendritic cell vaccination and adoptive T-cell therapy had been used in ovarian cancer and that it was successful, even producing a complete remission in one patient and had few — if any — side effects. She discussed the therapy with Peter Goodwin.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/130407LanaKandalaftPODCASTLoRes.mp3]
Related Episodes
More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths
An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Ce
Fast, Accurate Artificial Intelligence Method to Diagnose and Classify Pediatric Sarcoma Anywhere
An interview with: Adam Thiesen, PhD Candidate, UConn Health, University of Connecticut and the Jackson Laboratory for Genomic Medicine, Farmington, CT And with: Jayesh Desai MD, Medical Oncologist,
Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer
An interview with: Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institut